Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel medicines. Its Recursion operating system enables advanced machine learning approaches to reveal drug candidates, mechanisms of action, novel chemistry, and potential toxicity, with the eventual goal of decoding biology and advancing new therapeutics that radically improve people's lives. The company was founded by Blake Borgeson, Christopher C. Gibson, and Dean Y. Li on November 5, 2013 and is headquartered in Salt Lake City, UT.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Bayer AG

BERLIN & SALT LAKE CITY--(BUSINESS WIRE)--Bayer and US-based Recursion Pharmaceuticals, Inc., a clinical stage TechBio company decoding biology to industrialize drug discovery, today announced that they have updated the focus of their research collaboration to precision oncology. The oncology-focused collaboration will leverage Bayer's small molecule compound library and expertise in biology and medicinal chemistry as well as Recursion's purpose-built artificial intelligence-guided drug discove.

Bayer and Recursion focus research collaboration on Oncology

Digitally enabled drug discovery for oncology has the potential to accelerate the delivery of new cancer therapies to patients. Drug discovery research collaboration may initiate up to seven oncology programs and further strengthens Bayer's early pipeline in precision oncology. Recursion is eligible to receive up to $1.5 billion in potential development and commercial milestone payments plus royalties. Digitally enabled drug discovery for oncology has the potential to accelerate the delivery of new cancer therapies to patients. Drug discovery research collaboration may initiate up to seven oncology programs and further strengthens Bayer's early pipeline in precision oncology. Recursion is eligible to receive up to $1.5 billion in potential development and commercial milestone payments plus royalties.

Bayer and Recursion Focus Research Collaboration on Oncology

With additional patient-centric data, compute power, and an exciting new focus for its Bayer collaboration, the company is accelerating the shift of biotech to techbio With additional patient-centric data, compute power, and an exciting new focus for its Bayer collaboration, the company is accelerating the shift of biotech to techbio

Recursion Announces Data Collaboration Deal with Tempus, Top 50 Supercomputer Ambition Powered by NVIDIA, and Updated Focus of Collaboration with Bayer to Precision Oncology

SALT LAKE CITY, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today reported business updates and financial results for its third quarter ending September 30, 2023.

Recursion Provides Business Updates and Reports Third Quarter 2023 Financial Results

SALT LAKE CITY, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced its participation in the following investor conference:

Recursion to Participate in Upcoming Investor Conference

Archer Aviation

PagerDuty

Roblox

Teradyne

Twilio

In the dynamic world of investing, Cathie Wood stocks continue to draw both bullish advocates and bearish critics. Cathie Wood's Ark Invest isn't your conventional ETF or mutual fund manager.

The 7 Best Cathie Wood Stocks to Buy Now: November Edition

Recursion is forging key relationships with powerful collaborators. The young biotech's valuation is also looking a lot better now.

2 Reasons to Buy Recursion Pharmaceuticals, and 1 Reason to Sell

Anghami

Tilray Brands

Speculative stocks are a risky proposition in today's market. With even the Standard and Practices (S&P) 500's stablest giants dropping, small-cap risky stocks don't stand a chance.

3 Extra-Speculative Stocks That Could Make You Very, Very Rich

Madrigal Pharmaceuticals

Recursion Pharmaceuticals is looking to introduce a paradigm shift in the way biotechs develop drugs. Madrigal Pharmaceuticals developed a therapy for a disease that has eluded many of its larger peers.

2 Risky Stocks With Massive Potential

Moderna

The AI in healthcare market may be worth more than $190 billion by the end of this decade, making it a great place to look for investing opportunities. It's important to consider the whole picture when choosing a stock instead of betting only on the company's AI program.

1 Artificial Intelligence Stock to Buy Hand Over Fist in October and 1 to Avoid

Recursion Pharmaceuticals is using a novel and promising approach to drug discovery. Its strategy has produced some candidates, but none yet seems close to approval.

Is Recursion Pharmaceuticals Stock a Buy Now?

Beam Therapeutics

Investor Cathie Wood has an eye for powerful trends in high-tech areas of the market. She has been hitting the buy button lately on Beam Therapeutics and Recursion Pharmaceuticals.

2 Cathie Wood Stocks I'm Bullish On

C3.ai

Shares of Recursion Pharmaceuticals and C3.ai spiked this year due to AI. Both business are unprofitable, however, and that's not likely to change soon.

2 AI Stocks That Aren't Worth the Hype

Exact Sciences

Cathie Wood is a thematic investor focused on disruptive new technologies. Recursion Pharmaceuticals could radically transform the drug discovery/development process.

2 Cathie Wood Stocks That Could Deliver Exponential Returns

Ginkgo Bioworks Holdings

Now's a great time to invest in biotechs that have AI as a tailwind. Ginkgo Bioworks uses AI to run bioengineering projects for other biotechs.

Better AI Biotech Stock: Ginkgo Bioworks vs. Recursion Pharmaceuticals

Eli Lilly

Biotech has long seemed to move slower than its fellow tech fields due to the complexity of biological systems and the difficulty of drug regulations. However, that precedent is set to change thanks to the growing implementation of artificial intelligence ( AI ), upending the field and bringing big changes to the industry.

Immunomics Stocks: 3 Ways to Play This Massive AI-Biotech Megatrend

SomaLogic

Beam Therapeutics is pioneering a promising type of gene editing. Recursion Pharmaceuticals is harnessing AI to improve drug discovery.

3 Stocks Cathie Wood Is Buying That Should Be on Your List, Too

CRISPR Therapeutics

The timing of upcoming catalysts is a key consideration when comparing biotechs. Recursion Pharmaceuticals may make more revenue soon, but not from its pipeline.

Better Growth Stock: Recursion Pharmaceuticals vs. CRISPR Therapeutics

ExScientia Ltd

Schrodinger 

Schrödinger uses AI to drive revenue for both of its segments. Recursion got a big boost from computer chipmaker Nvidia.

3 AI Drug Discovery Stocks to Watch

Recursion Pharmaceuticals is a clinical-stage biotechnology company that uses AI and experimental biology to discover new treatments for diseases. The company has a technology platform called Recursion OS, which includes a collection of images, a search engine, a cloud-based supercomputer, and software tools. Recursion Pharmaceuticals has a diverse pipeline of over 40 programs in various stages of development, with lead candidates targeting rare genetic disorders and common complications of diseases.

Recursion Pharmaceuticals: Leveraging AI To Decode Biology And Discover Novel Therapeutics

bluebird bio

The consensus price target for Recursion Pharmaceuticals suggests the stock can soar 88% from recent prices. The average analyst estimates for bluebird bio stock imply a gain of 99% over the next 12 months.

2 Growth Stocks That Could Rocket 88% to 99% Higher According to Wall Street

Recursion Pharmaceuticals has three different business segments that could grow. Its drug development pipeline will take the longest to yield sales.

Where Will Recursion Pharmaceuticals Be in 3 Years?

Amid fierce debate about prescription-drug prices and countless proposals to rein them in, there has been a point of widespread agreement: Those prices at least partly reflect the vast amount of time, money and risk involved in developing new medicines.

Recursion Pharmaceuticals has a prescription for high drug costs: AI and 25 petabytes of data

CRISPR Therapeutics is awaiting the FDA's approval decision on its most advanced treatment candidate. Recursion Pharmaceuticals is a clinical-stage drugmaker applying artificial intelligence to the drug-discovery process.

2 Brilliant Growth Stocks With Upsides of About 70%, According to Wall Street

AbbVie

Vertex Pharmaceuticals

In the grand tapestry of the investment world, one thread that continues to shine is biotech stocks to buy and hold. It's no secret that delving into biotech investments can be incredibly challenging, even when zeroing in on established firms with market-ready drugs and expansive research and development pipelines.

3 Biotech Stocks to Invest In for Big-Time, Long-Term Gains

News for Recursion Pharmaceuticals Stock (RXRX)